Daré Bioscience Expands Women’s Health Portfolio

Daré Bioscience ( (DARE) ) has released its Q1 earnings. Here is a breakdown of the information Daré Bioscience presented to its investors.

Daré Bioscience is a biopharmaceutical company focused on developing innovative solutions for women’s health, addressing areas such as contraception, sexual health, and menopause. The company is leveraging existing clinical data to bring products to market efficiently.

In its first quarter of 2025, Daré Bioscience reported a strategic expansion with plans to commercialize multiple women’s health solutions, including Sildenafil Cream and vaginal probiotics, aiming to start generating revenue by the fourth quarter of this year. The company is also preparing to launch a monthly hormone therapy in 2026.

Key financial highlights include a decrease in operating expenses, with general and administrative expenses dropping to $2.3 million from $2.7 million in the previous year, and research and development expenses decreasing by 31%. Despite these reductions, the company reported a net loss of $4.4 million, an improvement from the $6.8 million loss in the same quarter last year.

Daré’s pipeline includes Ovaprene, a hormone-free contraceptive currently in Phase 3 trials, and DARE-HPV, targeting HPV-related cervical diseases. The company is actively engaging with the FDA to advance its Sildenafil Cream into Phase 3 trials.

Looking forward, Daré Bioscience aims to capitalize on its unique position in the women’s health sector by rapidly commercializing products through multiple channels, including compounded drugs and consumer health products, while continuing to seek FDA approvals.